{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-336886","form_type":"8-K","ticker":"CGON","cik":"0001991792","company_name":"CG Oncology, Inc.","filed_at":"2026-08-06T12:30:16+00:00","discovered_at":"2026-08-06T12:35:01.361498+00:00","generated_at":"2026-08-06T12:35:38.314821+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CG Oncology Q2 net loss $79.1M ($0.90/shr); adds $500M ATM capacity","bullets":["Net loss of $79.1M ($0.90 per share) vs $41.4M ($0.54) in Q2 2025; R&D $54.7M, G&A $29.0M.","Cash, equivalents and marketable securities $1.0B as of June 30, 2026, down from $1.1B on March 31, 2026.","Filed Amendment No. 2 to Prospectus to increase ATM shares by $500M (previously sold ~$550M).","PIVOT-006 Phase 3 topline data for cretostimogene in intermediate-risk NMIBC expected near-term.","BLA submission for HR BCG-unresponsive NMIBC with CIS expected Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-336886","json":"https://secwatch.observer/filing/0001193125-26-336886.json","markdown":"https://secwatch.observer/filing/0001193125-26-336886.md","text":"https://secwatch.observer/filing/0001193125-26-336886.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1991792/000119312526336886/0001193125-26-336886-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1991792/000119312526336886/ck0001991792-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T12:35:38.314821+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}